All In Biotech

Investigational drug · Phase 2

DYP688

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Uveal Melanoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "DYP688"

First trial start

2022

Jul 4, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DYP688", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Uveal Melanoma

Approved drugs for the same conditions: Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "DYP688" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Metastatic Uveal Melanoma

  • DarovasertibIDE 196, LXS196Phase 35 trials

    IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma

  • RP2Phase 32 trials

    Replimune, Inc. · Hepatocellular Carcinoma, Biliary Tract Cancer, Metastatic Uveal Melanoma

  • VMD-102Single agentPhase 21 trial

    VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.